PQ Pharmacy, LLC

Has PQ Pharmacy, LLC received an FDA warning letter about GLP-1 drugs?

Yes. FDA issued PQ Pharmacy, LLC a warning letter naming semaglutide, dated Oct 10, 2025, with the FDA subject line “Compounding Pharmacy/Adulterated Drug Products.”

FDA records in this index name PQ Pharmacy, LLC on Oct 10, 2025. It is listed on FDA’s registered 503B outsourcing facility list: PQ Pharmacy LLC, Brooksville, FL.

Type named in FDA records
Compounding pharmacy, 503B outsourcing facility
FDA warning letters
1
Drug recall reports
0
Drugs named
Semaglutide
Latest record
Oct 10, 2025
503B location
Brooksville, FL
503B last inspection
Jun 1, 2026
Form 483 issued
Yes
Action on last inspection
Open

FDA warning letters

Later letters FDA listsLetter
Oct 10, 2025Compounding Pharmacy/Adulterated Drug ProductsSemaglutideNone listed by FDA as of Nov 15, 2026fda.gov

A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.

FDA’s summary excerpts

Drug recalls

No openFDA drug recall reports in this index.

FDA compounding inspections and actions

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists one facility under this exact legal name. These entries cover all of the facility’s compounding, not only GLP-1 drugs.

PQ Pharmacy, LLC, Brooksville, FL (503B)

6 listed actions, including 4 Form 483s and 1 warning letter (2022 to 2026).

Document
Jun 1, 2026Form 483483 Issued 06/01/2026fda.gov
Oct 10, 2025Warning letterWarning Letter (10/10/2025)fda.gov
Apr 4, 2025Form 483483 issued 04/04/2025fda.gov
Mar 30, 2023FMD-145 letterFMD-145 Letter Issued 3/30/2023Not linked by FDA
Nov 17, 2022Amended Form 483Amended 483 Issued 11/17/2022FDA copy (archived)
Oct 27, 2022Form 483483 Issued 10/27/2022fda.gov

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.

Pharmacy pages with the same legal name, built from FDA’s 503B list and compounding inspections and actions page: PQ Pharmacy LLC, Brooksville, FL.

FDA NDC listings

FDA’s NDC Directory files, read Nov 15, 2026, list 7 products naming liraglutide, semaglutide and tirzepatide under the labeler name “PQ Pharmacy LLC”, matched to this company page by exact name. Marketing categories as FDA gives them: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (7). The compounded product reports cover FDA reporting periods 2024-2 to 2025-2.

Reporting periods
81375-606LiraglutideLiraglutideINJECTIONSUBCUTANEOUS6 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-2Compounded drugs
81375-614LiraglutideLiraglutideINJECTIONSUBCUTANEOUS15 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-2Compounded drugs
81375-600SemaglutideSemaglutide 2.5mg/mLINJECTION, SOLUTIONSUBCUTANEOUS2.5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1Compounded drugs
81375-601SemaglutideSemaglutideINJECTION, SOLUTIONSUBCUTANEOUS1 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1Compounded drugs
81375-605SemaglutideSemaglutide 5mg/mLINJECTION, SOLUTIONSUBCUTANEOUS5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1Compounded drugs
81375-610TirzepatideTirzepatideINJECTION, SOLUTIONSUBCUTANEOUS10 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1Compounded drugs
81375-620TirzepatideTirzepatideINJECTION, SOLUTIONSUBCUTANEOUS20 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1Compounded drugs

FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” The compounded file gives no marketing dates; its reporting period is shown as FDA writes it.

FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.